Navamedic to strengthen its largest product

Navamedic ASA (OSE: NAVA) today announced that the Company is stepping up the marketing of its largest product, Ovesterin, in order to benefit from an improved market potential.

Ovesterin is used by women experiencing estrogen deficiency and discomfort during and after the menopause. The product is part of Navamedic's Female Care strategic product group and enjoys a unique market position. Ovesterin represents annual sales of more than NOK 30 million in the Nordic markets.

Increasing demand for the product has caused Navamedic to intensify marketing of Ovesterin. The marketing of the product is a joint effort with and financed by Ovesterin's manufacturer, Navamedic's main partner Aspen.

Navamedic has worked closely with supplier of pharma products Aspen of South Africa since 2010, and Aspen is the Company's main supplier. The expanded joint marketing of Ovesterin in the Nordic region reflects the strong partnership between the two companies.

For further information, please call Håkan Josephsson, acting CEO, telephone +46 706 742 533 or Bjørn Lindholt, CFO, telephone +47 9300 6601.

Navamedic ASA is a Norwegian pharmaceutical products company, marketing and distributing more than 120 products in the Nordic and Benelux markets. The Company operates three business areas; Pharma Products, Medical Nutrition and Consumer Care based on its relationship with a number of pharmaceutical product manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).